Eszopiclone and Ocrevus drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eszopiclone (eszopiclone) and Ocrevus (ocrelizumab). Common drug interactions include fatigue among females and chest pain among males.

The phase IV clinical study analyzes what interactions people have when they take Eszopiclone and Ocrevus. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Eszopiclone?

Eszopiclone has active ingredients of eszopiclone. It is often used in insomnia. eHealthMe is studying from 4,258 Eszopiclone users. Check the latest studies of Eszopiclone.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.



On Jul, 19, 2026

13 people who take Eszopiclone and Ocrevus together, and have interactions are studied.

Eszopiclone and Ocrevus drug interactions.

What are the common drug interactions of Eszopiclone and Ocrevus, by gender? *:

female:

  1. Fatigue (feeling of tiredness)
  2. Blood pressure increased
  3. Headache (pain in head)
  4. Heart rate increased
  5. Muscle spasms (muscle contraction)
  6. Oral herpes (viral infection of mouth)
  7. Pyrexia (fever)
  8. Torticollis (a twisted neck in which the head is tipped to one side, while the chin is turned to the other)
  9. Dyspnoea (difficult or laboured respiration)
  10. Conjunctivitis (pink eye)

male:

  1. Chest pain
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Limb discomfort (discomfort in leg)
  4. Speech disorder
  5. Asthenia (weakness)
  6. Discomfort
  7. Dizziness
  8. Nephrolithiasis (calculi in the kidneys)
  9. Urinary tract infection

What are the common drug interactions of Eszopiclone and Ocrevus, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Fatigue (feeling of tiredness)
  2. Anxiety
  3. Blood pressure increased
  4. Dyspnoea (difficult or laboured respiration)
  5. Headache (pain in head)
  6. Heart rate increased
  7. Muscle spasms (muscle contraction)
  8. Oral herpes (viral infection of mouth)
  9. Pyrexia (fever)
  10. Torticollis (a twisted neck in which the head is tipped to one side, while the chin is turned to the other)

40-49:

  1. Anxiety
  2. Blood pressure increased
  3. Fatigue (feeling of tiredness)
  4. Headache (pain in head)
  5. Heart rate increased
  6. Muscle spasms (muscle contraction)
  7. Oral herpes (viral infection of mouth)
  8. Pyrexia (fever)
  9. Torticollis (a twisted neck in which the head is tipped to one side, while the chin is turned to the other)

50-59:

  1. Chest pain
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Anxiety
  4. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  5. Cataract (clouding of the lens inside the eye)
  6. Contusion (a type of hematoma of tissue in which capillaries)
  7. Depression
  8. Drug hypersensitivity
  9. Dyspnoea (difficult or laboured respiration)
  10. Infusion related reaction

60+:

  1. Urinary tract infection
  2. Conjunctivitis (pink eye)
  3. Discomfort
  4. Dizziness
  5. Nephrolithiasis (calculi in the kidneys)
  6. Immunosuppression
  7. Limb discomfort (discomfort in leg)
  8. Memory impairment
  9. Paranasal sinus discomfort
  10. Sinusitis (inflammation of sinus)

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 46.15%
  2. Neuralgia (pain in one or more nerves): 3 people, 23.08%
  3. Muscle Spasms (muscle contraction): 3 people, 23.08%
  4. Nephropathy (damage to or disease of a kidney): 2 people, 15.38%
  5. High Blood Pressure: 2 people, 15.38%
  6. Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 2 people, 15.38%
  7. Seasonal Allergy (allergic condition due to certain season): 2 people, 15.38%
  8. Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 2 people, 15.38%
  9. Pain: 2 people, 15.38%
  10. Oral Herpes (viral infection of mouth): 2 people, 15.38%

* Approximation only. Some reports may have incomplete information.

Do you take Eszopiclone and Ocrevus?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Eszopiclone and Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Eszopiclone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eszopiclone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ocrevus and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on eszopiclone and ocrelizumab (the active ingredients of Eszopiclone and Ocrevus, respectively), and Eszopiclone and Ocrevus (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: